Skip to main content

Table 1 Genome-wide association study summary data used for the Mendelian randomization analyses

From: The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development

Category

Trait

Unit

Population and measure

Sample size

Citation

Biomarker

Plasma citrate

SD

European ancestry UK Biobank participants, using cross-sectional measurements

115,064

[29]

Plasma calcium

SD

British ancestry UK Biobank participants, using cross-sectional measurements

361,194

[30]

Renal

Creatinine-eGFR

SD of log

Multi-ancestry GWAS meta-analysis, using cross-sectional measurements and formulae as described in the original study

1,201,929

[31]

Cystatin C-eGFR

SD of log

Blood urea nitrogen

SD of log

Urine albumin-creatinine ratio

SD of log

Multi-ancestry GWAS meta-analysis, using spot measurements in a population including 51,541 individuals with diabetes

564,257

[32]

Chronic kidney disease

Log OR

Multi-ancestry GWAS meta-analysis, with case definitions as those with cross-sectional eGFR measurements < 60 mL/min/1.73m2

625,219 (64,164 cases)

[33]

Microalbuminuria

Log OR

Multi-ancestry GWAS meta-analysis, defined as urine albumin-creatinine ratio > 30 mg/g in spot measurements

348,954 (51,861 cases)

[32]

Metabolome

1296 plasma metabolites

SD

German Chronic Kidney Disease study, using cross-sectional measurements in individuals with eGFR 30-60 ml/min/1.73m2, or eGFR > 60 ml/min/1.73m2 with urine albumin-creatinine ratio > 300 mg/per g, or urinary protein/creatinine ratio > 500 mg/g

5023

[34]

1399 urine metabolites

SD

Lipid, glucose and inflammation

Plasma low-density lipoprotein cholesterol

SD

European ancestry GWAS meta-analysis, using cross-sectional measurements

1,320,016

[35]

Plasma high-density lipoprotein cholesterol

SD

Plasma triglycerides

SD

Fasting plasma glucose

mmol/l

European ancestry GWAS meta-analysis, using cross-sectional measurements

200,622

[36]

Imaging-derived liver fat (MRI-PDFF)

SD

UK Biobank participants, using cross-sectional measurements

36,703

[37]

Plasma interleukin 6 binding aptamer level

SD

deCODE Icelandic study, using cross-sectional measurements

35,559

[38]

Plasma C-reactive protein level

SD of log

European ancestry GWAS, using cross-sectional measurements

427,367

[39]

Proteome

4907 plasma protein-binding aptamers

SD

deCODE Icelandic study, using cross-sectional measurements

35,559

[38]

  1. The full list of analysed metabolites and protein-binding aptamers are available in Additional file 2. Full study details and access to GWAS summary data are provided in the original publications. Exclusions were not made for individuals with polycystic kidney disease or renal stone disease. BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, GWAS genome-wide association study, MRI-PDFF magnetic resonance imaging-derived proton density fat fraction, OR odds ratio, SD standard deviation, uACR urine albumin-creatinine ratio